Effective January 26, 2023 : Texas Medicaid Preferred Drug List Updates
Date: 01/06/23
Texas Health and Human Services (HHS) will publish the semi-annual update of the Texas Medicaid Preferred Drug List on Thursday January 26, 2023. The update will be based on changes presented at the Vendor Drug Program (VDP) Drug Utilization Review (DUR) Board meetings in July and October 2022. Superior HealthPlan follows the Texas Medicaid Vendor Drug Formulary and the PDL.
The tables below summarize some of the anticipated noteworthy changes from the July 2022 and October 2022 DUR meetings.
Please note: The tables are not the complete list of changes. Please reference the Texas Medicaid PDL for a complete list of recommended medications or visit DUR Board webpage on the Texas Vendor Drug website for all decisions.
Table below includes the January PDL update changes based on the July PDL decisions:
PDL Class | Drug | Current PDL Status | Recommended Status |
|---|---|---|---|
Alzheimer’s Agents | Adlarity (transderm) | Non-reviewed | Non-preferred |
Calcium Channel Blockers | Norliqva (oral) | Non-reviewed | Non-preferred |
Cytokine and CAM Antagonists | Cibinqo (oral) | Non-reviewed | Non-Preferred |
Fluoroquinolones, oral | Cipro suspension (oral) | Non-Preferred | Preferred |
Fluoroquinolones, oral | Ciprofloxacin suspension (oral) | Preferred | Non-Preferred |
Glucocorticoids, oral | Tarpeyo (oral) | Non-reviewed | Non-Preferred |
Immunosuppressives, oral | Tavneos (oral) | Non-reviewed | Non-preferred |
Non-steroidal anti-Infallatory Drugs (NSAIDs) | Diclofenac sodium (oral) | Non-Preferred | Preferred |
Non-steroidal anti-Infallatory Drugs (NSAIDs) | Ketorolac (oral) | Non-Preferred | Preferred |
Non-steroidal anti-Infallatory Drugs (NSAIDs) | Sulindac (oral) | Non-Preferred | Preferred |
Ophthalmic Antibiotics | Vigamox (ophthalmic) | Non-Preferred | Preferred |
Ophthalmic Antibiotic-Steroid Combinations | Tobradex suspension (ophthalmic) | Non-Preferred | Preferred |
Ophthalmics for Allergic Conjunctivitis | Lastacaft, OTC (ophthalmic) | Non-reviewed | Non-Preferred |
Ophthalmics for Allergic Conjunctivitis | Olopatadine, OTC (pataday once daily) (ophthalmic) | Non-Preferred | Preferred |
Ophthalmics for Allergic Conjunctivitis | Olopatadine, OTC (pataday twice daily) (ophthalmic) | Non-Preferred | Non-Preferred |
Rosacea Agents, topical | Epsolay (topical) | Non-reviewed | Non-Preferred |
Skeletal Muscle Relaxants | Fleqsuvy (oral) | Non-reviewed | Non-preferred |
Skeletal Muscle Relaxants | Lyvispah (oral) | Non-reviewed | Non-Preferred |
Ulcerative Colitis | Canasa (rectal) | Non-preferred | Preferred |
Ulcerative Colitis | Mesalamine (Canasa) (AG) (rectal) | Preferred | Non-preferred |
Ulcerative Colitis | Mesalamine (Canasa) (rectal) | Preferred | Non-Preferred |
Ulcerative Colitis | Pentasa (oral) | Non-preferred | Preferred |
Uterine Disorder Treatments (new PDL class) | Myfembree (oral) | Non-reviewed | Preferred |
Uterine Disorder Treatments (ew PDL class) | Oriahnn (oral) | Non-reviewed | Preferred |
Uterine Disorder Treatments (new PDL class) | Orilissa (oral) | Non-reviewed | Preferred |
Acne Agents, topical | Twyneo, cream (topical) | Non-reviewed | Non-Preferred |
Analgesics, narcotics short | Seglentis (oral) | Non-reviewed | Non-Preferred |
Antivirals, orals | Livtencity (oral) | Non-reviewed | Non-Preferred |
Colony Stimulating Factors | Releuko, syringe (subcutaneous) | Non-reviewed | Non-Preferred |
Colony Stimulating Factors | Releuko, vial (injection) | Non-reviewed | Non-Preferred |
Gastrointestinal (GI) Motility, chronic | Ibsrela, tablet (oral) | Non-reviewed | Non-Preferred |
Hereditary Angiodeema (HAE) Treatments | Takhzyro, syringe (sub-q) | Non-reviewed | Non-Preferred |
HIV/AIDS | Triumeq PD tab suspension (oral) | Non-reviewed | Preferred |
Opiate Dependence Treatments | Zimhi (injection) | Non-reviewed | Preferred |
Acne Agents, topical | Twyneo, cream (topical) | Non-reviewed | Non-Preferred |
Analgesics, narcotics short | Seglentis (oral) | Non-reviewed | Non-Preferred |
Antivirals, orals | Livtencity (oral) | Non-reviewed | Non-Preferred |
Colony Stimulating Factors | Releuko, syringe (subcutaneous) | Non-reviewed | Non-Preferred |
Colony Stimulating Factors | Releuko, vial (injection) | Non-reviewed | Non-Preferred |
Gastrointestinal (GI) Motility, chronic | Ibsrela, tablet (oral) | Non-reviewed | Non-Preferred |
Table below includes the January PDL update changes based on the October PDL decisions:
PDL Class | Drug | Current PDL Status | Recommended Status |
|---|---|---|---|
Androgenic Agents | Androderm (transderm) | Non-preferred | Preferred |
Antibiotics, vaginal | Xaciato (vaginal) | Non-reviewed | Non-preferred |
Antiemetics/Antivertigo agents | Diclegis (oral) | Non-preferred | Preferred |
Antiemetics/Antivertigo agents | Transderm-scop (transderm) | Non-Preferred | Preferred |
Antipsychotics | Rexulti (oral) | Non-Preferred | Preferred |
Colony Stimulating Factors | Fulphila (subcutaneous) | Preferred | Non-Preferred |
Colony Stimulating Factors | Nyvepria (subcutaneous) | Non-Preferred | Preferred |
Epinephrine, self-injected | Epipen (intramusc) | Non-Preferred | Preferred |
Epinephrine, self-injected | Epipen Jr (intramusc) | Non-Preferred | Preferred |
Hypoglycemics, incretin mimetics/enhancers | Mounjaro (subcutane) | Non-reviewed | Non-Preferred |
Hypoglycemics, incretin mimetics/enhancers | Ozempic (subcutane) | Non-Preferred | Preferred |
Hypoglycemics, incretin mimetics/enhancers | Trijardy XR (oral) | Non-Preferred | Preferred |
Hypoglycemics, metformin | Glumetza (oral) | Non-Preferred | Preferred |
Hypoglycemics, metformin | Metformin ER (Glumetza) (oral) | Preferred | Non-Preferred |
Hypoglycemics, SLGT2 | Invokamet (oral) | Non-preferred | Preferred |
Macrolides-Ketolides | E.E.S. 200 suspension (oral) | Preferred | Non-preferred |
Macrolides-Ketolides | Eryped 200 suspension (oral) | Non-Preferred | Preferred |
Tetracyclines | Doxycycline Monohydrate 100 mg capsule (AG) (oral) | Non-preferred | Preferred |
Tetracyclines | Doxycycline Monohydrate 50 mg capsule (AG) (oral) | Non-Preferred | Preferred |
Oncology, oral - Hematologic | Vonjo (oral) | Non-reviewed | Preferred |